Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$8.00 WOW!
Seeking Alpha Article 11/20/2013
Alliqua Inc. Amplifies Value Proposition With Celgene's Licensing Deal
Nov 20 2013, 08:45 | about: ALQAD, includes:
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
The wound therapy industry may not be the most thrilling biotech niche on the surface, but the multi-billion dollar market's need for innovation has created an opportunity for small prospecting companies operating in the space. Research from the Kalorama Institute forecasts the wound care segment of medicine to reach approximately $21 billion by 2015, a 25% growth from 2012's figure at $16.8 billion, presenting vast potential for companies who can differentiate their technology from the standard of care in the respective division. Dominant players in the space like Johnson & Johnson (JNJ), ConvaTec (former division of Bristol-Myers Squibb), Kinetic Concepts (KCI) and Smith & Nephew (SNN) make up over half the overall market, subsequently drawing attention away from the up-and-coming companies innovating the industry. The opportunity for investors to realize compound growth as the market cultivates, lies in the success of smaller companies penetrating the market, potential not offered from larger corporations whose stock performance can be diluted from a diverse product portfolio stretching across different market segments.
Is Alliqua Poised To Penetrate The Wound Care Market?
Alliqua (OTCQB:ALQAD) is a biopharmaceutical corporation focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Their proprietary technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. In the area of transdermal drug delivery, the hydrogel technology can be used to deliver therapeutic compounds through the skin. Key benefits of the delivery platform include stability of form and composition, purity, reproducibility, and compatibility with various active ingredients, sporting multiple advantages over oral drug delivery or injections.
In addition to the four products the company already derives revenue from; SilverSeal, Hydress, Sorbion Sachet S and Sorbian Sana (FDA 510k approved with Medicare reimbursement), the real buzz surrounding the company stemmed from the announcement on Tuesday November 19th, when Alliqua entered into a licensing agreement with the pharmaceutical giant Celgene Celluar Therapeutics, a subsidiary of Celgene Corporation (CELG), whereby Alliqua received the exclusive right to develop and market the advanced wound care products Biovance and Extracellular Matrix (ECM). Biovance is a collagen-based decellularized and dehydrated biologic wound covering produced from human amniotic membrane while ECM is a suite of advanced wound management products made from extracellular matrix derived from the human placenta. Together, the two wound care products will be developed harnessing Alliqua's proprietary technology, offering a product with immense potential to penetrate the market with the support and conviction from one of the utmost trusted names in the industry, Celgene.
Concurrent with the licensing deal, Alliqua entered into an agreement with Celgene to sell 1,672,474 shares of common stock, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In addition to the transaction with Celgene, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested $7 million on comparable financial terms that was announced earlier in the month. The recent influx of capital has removed concerns over the company's financial situation (Cash on hand was only $420,000 in September), while ensuring that Alliqua will have significant capital to bring its business objectives to fruition.
Reverse Stock Split and Bolstered Cash Position: First Steps To Uplist
Disclosed in a press release a day prior to the deal with Celgene, on Monday November 18th, Alliqua outlined its intentions to uplist to a national securities exchange whilst announcing that there will be a 43.75:1 reverse stock split. As a result of the Reverse Split, the number of outstanding common shares was reduced from 310,993,023 to approximately 7,108,412, ultimately bringing the share price to an open price of $5.00/share which satisfies the condition of a minimum share price required by all national exchanges. Uplisiting to a national exchange like the NYSE-MKT or NASDAQ-CM generates advantages in broader visibility, increased liquidity and accessibility to the deep pockets of institutional investment firms and retail brokers. This has been witnessed many times throughout the past, with a great example of the benefits uplisting offers being realized by Organovo (ONVO), a company whose share price soared from $3.90 to $8.50 on the news of the uplist alone. This was accommodated with an influx of institutional investment and substantial increase in the trading volume, facilitating the stock to trade at its current levels today. In the case of Alliqua, there seems to be a sort of anomaly where institutional investment has already made its way in, uncommon as many institutional investors stray away from OTC securities. At the same time, while it's promising seeing institutional money flow in, it simultaneously gives the company the opportunity to uplist bringing the cash balance high enough to satisfy national exchange requirements.
Alliqua's Management Team: One of the Company's Strongest Assets
Putting the vast implications of the deal with Celgene into perspective, it may not come as a surprise to learn that Alliqua's Chairman is Jerome Zeldis, the Chief Medical Officer veteran of Celgene since 1997. From that time, Celgene's market capitalization grew from $100M to over $60B, attributed greatly due to the efforts and hard work of Mr. Zeldis. Of equal magnitude, the CEO David Johnson, was the former CEO of Bristol-Meyers Squibb's ConvaTec (Wound Care & Ostomy segment) where he grew revenues to $1.7B and oversaw its sale for $4.1B. With the combined background of expertise, connections and immense relevant credentials supported by both executives in conjunction with the company's expanding proprietary technology portfolio, Alliqua arguably has all the key ingredients that formulate a successful biopharmaceutical company. With Biovance poised to launch in Q2 of 2014 and ECM in Q2 2015 respectively, alongside with anticipated uplisting, retail investors seeking exposure to the niche markets of innovative wound care still have a chance to invest before the monetary benefits of the aforementioned events come into play.
Here's the Celgene news release.. GREAT NEWS!!!
Alliqua Announces Transaction with Celgene
Alliqua Receives License to Celgene Cellular Therapeutics Advanced Wound Care Products
Celgene Invests $6.0 Million in Alliqua at $3.59 per Share
Alliqua Closes Additional $7 Million in Simultaneous Investment Transaction with New Investors
LANGHORNE, Pa.--Alliqua, Inc. (OTCQB:ALQA) (“Alliqua” or the “Company”) entered into a licensing agreement with Celgene Cellular Therapeutics (“CCT”), a subsidiary of Celgene Corporation (NASDAQ:CELG) (“Celgene”), whereby Alliqua received the right to develop and market the advanced wound care products Biovance® and Extracellular Matrix (ECM). Concurrently with the license agreement, Alliqua entered into an agreement with Celgene to sell to Celgene 1,672,474 shares of common stock of Alliqua, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In connection with this agreement to invest in Alliqua’s securities, Celgene received a right to appoint a director to Alliqua’s Board of Directors. Concurrent to this transaction, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested an additional $7 million on comparable financial terms. Alere Financial Partners, a division of Summer Street Research Partners, acted as placement agent for the transaction with these investors.
Elaborating on the impact of this series of transactions, David Johnson, Chief Executive Officer of Alliqua, said, “Celgene is recognized as a leader in the biopharmaceutical sector. We welcome Celgene’s investment in Alliqua and the expertise we expect to gain from the representative they will appoint to join our Board of Directors. Today, our investors can see a much clearer picture of our business focus, which remains firmly fixed on building a company in the wound care space that is capable of offering a superior suite of technological solutions for wound care practitioners and their patients. Biovance® and ECM are complementary additions to our already well-received wound care portfolio that includes SilverSeal, Hydress and our other hydrogel-based products, as well as sorbion’s hydration response technology that was licensed earlier this year.”
Johnson concluded: “With the further addition of $7 million from an unrelated group of aligned investors, Alliqua now has significant capital to bring our business plans to fruition.”
Perry Karsen, Chief Executive Officer of Celgene Cellular Therapeutics, said, “Alliqua possesses the strength of leadership and the technical expertise necessary to convey the specific benefits of Biovance® to wound care practitioners and their patients, and to help us further advance ECM. Our agreement positions us to work in tandem as we communicate the benefits of these products. We greatly look forward to working with David and the rest of the Alliqua team to bring these important products to patients.”
Biovance® is a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane that is indicated for the management of non-infected partial- and full-thickness wounds. The product, which is ready for commercial use, is expected to be launched during the latter part of the second quarter 2014.
ECM is a suite of advanced wound management products made from extracellular matrix derived from the human placenta.
The investment by Celgene in Alliqua shares reflects the adjusted capitalization of the Company following a 43.75-for-1 reverse stock split that was effectuated on November 18, 2013. As recently announced, Alliqua is pursuing an uplisting to a national market.
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand, as well as the sorbion sachet S and sorbion sana wound care products. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Contacts
Alliqua, Inc.
Brian M. Posner, +1-215-702-8550
Chief Financial Officer
bposner@alliqua.com
or
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider, +1-212-825-3210
cschneider@dgicomm.com
or
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj, +1-212-825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
Released November 19, 2013
Crookedneck.. I agree with you about no CC
and that is what I said last week. I can't see him answering questions that he doesn't want to. That's why I was pushing for a PR and or Letter to shareholders.
So that being said and with the agreement he mentioned that these third qtr sales in 2013 cannot be realized until 1st qtr 2014 that gives me further pause to reflect on this.
That means that fourth qtr 2013 sales will not be realized until 1st qtr 2014. So we will not be seeing any sales figures until May 15, 2014.
4th qtr ends 12/31/13 and will show nothing again when reporting in Mar 2014 when they are due. (I believe 4th qtr numbers are due within 75 days of end of qtr., and if he reports on last day as he has been doing for each qtr, then nothing, so to speak, in Mid March)
1st qtr 2014 ending Mar 31 will not be reported until May 15, 2014. (45 days) So all of the third & fourth qtrs 2013 and 1st qtr 2014 wont be known until Mid May. The good thing is that should be one whopper of a report.
However, unless Mr James takes a more pro active approach concerning shareholder value, we have a stagnant share price. I am not selling, and will add to my position as funds come available. I see the value of the company, based on how Mr James is going about growing NRTI, done some research and read your reports to this board, BUT we need exposure if share price is to grow. I'm not telling him how to run the company, but he needs to get out there with some dog and pony shows, magazine interviews, radio interviews, etc. And that's where a reputable IR firm could be the route to take, but sooner rather than later.
DG
Any chance Abbott is in negotiations to purchase US rights for Vitaros from Activis and is delaying Canadian launch, preventing early success to negotiate lower buy out of those rights.
Just thinking.
ew86...wish I knew the answer.
From what I've seen they have a tremendous product.
According to their 3rd qtr numbers released on Friday, sales were slightly down, expenses up, and year over year outstanding shares increased by 2 million shares.
I've been in over a year and am underwater. Not sure if I should double up, averaging down or just pray to break even.
What are your thoughts?
However, I am not selling.. Too stubborn!
Dennis ... You are right...
Yes it is a manufacturer's coupon good anywhere. What led me to believe it was only Walgreens was under Martha's picture, it said "Now available at Walgreens".
I thought that meant it was only for Walgreens. Perhaps they are picking up some of the advertising cost.
If not, I think the insert should be updated to include Hyvees and indicate available on line too.
Walgreens coupon insert for MSE
In this weekend's coupon insert I found a Walgreens coupon for Martha Stewart essentials. two coupons, actually.. One for now and one for later.
Replay of the one used a few weeks ago, bottom half page, with a picture of Martha on the left and coupons on the right:
Save $2 Now on any 1 Martha Stewart Essential supplement, expires 1/31/2014
Save $2 Later on any 1 MSE supplement , expires 2/28/14
I never would have seen it if I hadn't been looking for it. A PR firm might have been helpful in issuing a release Thursday or Friday about the success of the product and to help introduce it to the Baby Boomers, look for money saving coupons in this weekends newspaper.
Conference Call sounds great.. I just dont think he will do it for two reasons, # 1, the expense and # 2, getting boxed into a corner with questions he does not want to hear.
My choice is PR, but what might be better is a letter to shareholders with a PR announcing it! Such a letter can elaborate about the growth of the company, expound on ALL its products and talk about the future. Perhaps Mr. James is planning this already!
Conference Call vs PR
How much do you think a CC would cost? How much is a PR?
How many investors would hear a CC vs how many more would read a PR?
I think a CC would be great, but just not yet. The CC would not have any analysts participating and how often does a firm conduct a CC to just its individual investors?
So in my mind, it boils down to the cost benefits of one outweighing the other. A PR could discuss the growth that has taken place, give a little peak at some of the activities planned and give a little guidance as to what revenues could be generated with maybe a glimpse at potential profits.
Plus he doesn't have to be put on the spot to answer anything he doesn't want to. He can be as specific or generic as he wants, just as long as he gets the word out.
You have done a great job of diseminating alot of info to us on the IHUB board, but how many people read this? We have 100 +/- followers.
Again, many thanks for all of the info and opinions your provide.
cn..maybe Mr James would like to reissue a new PR
The 3rd qtr announcement of earnings is very vague. A lot of people do not read the 10Q's and won't know about all of the deferred revenue. Yes, there are deferred expenses, but I think the investing public would feel a lot more confident if they saw the deferred revenues in writing.
It's time to hire a real investment relations firm and get some good PR out of what is happening. It doesn't have to be puff pieces, but no one will know about our "secret company" if the company doesn't toot its horn a little.
I'm not paniking or selling, as I know what a great company this can and will be. But this message board cannot support the share price, you in particular, forever!
Deferred Revenue Looks Pretty Good...
Revenue Recognition
Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments and estimated returns and upon transfer of title and risk to the customer which occurs at shipping (F.O.B. terms). Upon shipment to various customers when all performance obligations are met and collectability is reasonably assured revenue is recognized. Upon shipment to specific customers with the right of return the Company defers revenues as returns are not reasonably estimable. As of September 30, 2013, deferred revenue totaled $1,358,186.
Deferred Revenue and Deferred Cost of Goods Sold
Deferred revenue consists substantially of amounts billed or payments received in advance of revenue recognition. Deferred cost of goods sold as of September 30, 2013 of $607,806, related to deferred product revenues includes direct product costs. Once all revenue recognition criteria have been met, the deferred revenues and associated cost of goods sold are recognized.
Nice to know there is record revenue that will be booked next qtr. If sales continue then things will really be spectacular.
Unfortunately this explains why the share price has not done anything yet!
Patience....
jsbeach... Great analysis..
You mention:
2) Spain, France, Belgium, Luxembourg, Italy national approvals - No approvals as expected by this call, but the good news projected is that 4 out 5 approvals are expected by year-end!
Vitaros is approved in I think four European Countries and APRI enters into a marketing agreement with France who is not approved!
I can only hope that France is one of the 4 out of 5 expected to be approved by year end. Hopefully this agreement is based on some pretty good insight, wink, wink.
As I said yesterday, WS was not impressed with the CC and all we can do is wait some more. I am very disappointed, but will continue to hold. Can't even sell any covered calls anymore.. No premium..
eicoman... I heard alot of good info
From an informational standpoint, this was one of the better conference calls I have listened to in the past couple of years.
Disappointed in nothing more concrete in Canada. I know it is up to Abbott, but this waiting is burning a hole in our pockets. I know there was more disclosure about this then ever, but still left anxious about the situation.
And how would revealing the amount of upfront milestone payments hurt in negotiations. We know that it is $4 mil. If we were receiving a good payment in 4Q, it would help in negotiations with others. By not disclosing, IMO, the dollar amount can't be too high.
Sorry for spouting off.. I am done ranting. I will continue to hold and wait.
eico, DG and all others thanks for all your input.
No softball questions today!
Market not liking answers. last trade $1.93
So we wait some more..
GLTA
GOOD Questions by this woman!
eicoman.. nice job..
according to todays PR they heard you in most areas.
Thanks
eicoman....did you get any response from Argo or Cox
regarding the questions you submitted?
TIA
crookedneck...I forgot to give you this info
Bob Prag, President
The Del Mar Consulting Group, Inc.
(858) 361-1786
bprag@delmarconsulting.com
CN.. Thanks for passing along that idea.
So here's another!
You mention that he may want to utilize a highgrade consulting firm. I think Bob Prag of Del Mar Consulting may be appropriate. I have copied some info from his website.
The Del Mar Consulting Group, Inc. ("DCG") is renowned within the investment community as a leader in assisting and advising micro-cap and small-cap public companies in the areas of investor & media relations, strategic management planning, capital formation, and mergers & acquisitions. Founded in 1999 and wholly owned by Robert B. Prag, a seasoned professional who possesses a unique blend of talent and expertise from the capital markets, corporate finance, and corporate communications. DCG is dedicated to providing the highest level of "proactive" service to its clients and investment professionals alike.
Our compensation packages are almost always totally comprised of restricted equity, which puts our mindset and goals in lockstep with our client companies' Board, management and typical shareholder - to increase and maximize shareholder value through building a fundamentally strong enterprise while maintaining a liquid market for its shares.
We believe that the breadth of our services and skill sets, coupled with proven, real-world experience, makes DCG both unique and superior to any other firm of its kind. We work side-by-side with the executive management teams of our clients, counseling them on public company decorum, interacting with analysts and institutional investors, selecting investment bankers, exchange listing initiatives, strategic planning, business alliances, and merger & acquisitions initiatives. In short, we take an active roll in assisting our client companies in advancing their fundamental business prospects.
DCG has a thorough and complete understanding of the capital markets, M&A deal structures, and various structures involving capital formation. Since opening its doors in 1999, DCG client and constituent companies have completed debt and equity capital raises totaling well over $250 million.
CN... I know you said Mr James
does not want to use a paid stock promoter, but do you think he might consider being interviewed on a business talk radio show? I think right after these record earnings are announced in the next few days, would be a great time. Get the name out there and what is going on during this transformation!
Another stock I have issued a PR today that they were interviewed by Yorba Media, which hosts a daily radio show out of Dallas.. Interview could be 5, 10, 15 minutes +/- depending on how long he would want to answer questions. Below is some info taken from their website.
Business Talk Radio
WELCOME TO YORBA MEDIA
THE TRADERS NETWORK
BROADCAST LIVE - WEEKDAYS AT 1PM
CLEAR CHANNEL - KFXR/1190-AM - DALLAS
From the fast action of the trading pit...to the power brokers making the headlines...Michael Yorba interviews the front-page Titans about the latest in trading tools and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios. It's a fast moving, high energy show that presents stocks, commodities, bonds, forex and derivatives in a new light and keeps investors asking for more...
The Traders Network stays ahead of the curve by featuring leading market and business professionals, sophisticated technology, and the analytics needed to identify the most lucrative investment strategies.
Successful performance depends on finding the right opportunities.
So...Shift your thinking and join us as we deliver “tomorrow’s trade today” on The Traders Network weekdays from 1-3pm on KFXR/1190-AM.
Alliqua Receives $1M from Crossover Healthcare Fund, LLC to Pursue Key Wound Care Initiatives
Download PDF
LANGHORNE, Pennsylvania, November 12, 2013 /PRNewswire/ --
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), obtained $1 million in financing from Crossover Healthcare Fund, LLC, with the financing to be used to pursue the Company's key initiatives in the wound care space.
The financing comes in the form of units consisting of 250,000 shares of Series A Preferred Stock that are convertible into 11,111,111 shares of common stock of the Company, at a conversion price of $0.09 per share, subject to adjustment, and a warrant to purchase 5,555,555 shares of common stock at an exercise price of $0.10 per share. Holders of the Series A Preferred Stock are entitled to receive dividends at the rate of 6.00% per annum of the stated value of $4.00 per share (the "Stated Value") and a liquidation preference per share of 120% of such Stated Value. Unless previously converted, the Company is required to redeem the Series A Preferred Stock on October 21, 2015 at a redemption price per share equal to the Stated Value. Additional details about the financing and the Series A Preferred Stock will be disclosed in the Company's 8-K filing with the Securities and Exchange Commission.
Brian M. Posner, Chief Financial Officer at Alliqua, said, "We are pleased to welcome Crossover Healthcare Fund, LLC as our newest investor. This financing will help us advance our sales and marketing initiatives for our line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand, as well as the sorbion sachet S and sorbion sana wound care products."
In September 2013, Alliqua signed a long-term agreement with sorbion GmbH & Co. KG ("sorbion") to distribute the sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings. sorbion hydroactive wound care products will be distributed exclusively by Alliqua throughout all of the Americas.
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand, as well as the sorbion sachet S and sorbion sana wound care products. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Contact:
Brian M. Posner
Chief Financial Officer
+1-215-702-8550
bposner@alliqua.com
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider
+1-212-825-3210
cschneider@dgicomm.com
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
+1-212-825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
SOURCE Alliqua, Inc.
Released November 12, 2013
oldcoach... APRI and Baseball
Atleast we are rooting for success is APRI and get enjoyment out of Baseball. And remember Buck is a Yankee at heart! Great manager, which I am hoping APRI's management can do as well. and bring us the success we are awaiting.
Any chance North Bay can mine 1,000 oz of gold by December to cover the 1 Million??
eicoman and DG... See I knew you guys would be the right ones
I just finished reading the Sunday discussions and you guys raise all of the right points. I would never know how to express those ideas properly in writing, but you guys never cease to amaze me.
I know I am pushing it, but I think there are others that need to know our concerns and since you have volunteered to represent us. I suggest that you send a duplicate email to Cox and Pascoe in addition to Argot. And while I am at it maybe the analysts should be contacted too, so they ask real questions and not just lob up those softballs. So, to make it easier for you I went to APRI web site and copied that infomation below..
Thanks in advance.
Investor Relations:
Edward Cox
ecox@apricusbio.com
Richard Pascoe
rpascoe@apricusbio.com
Argot Partners
apricusIR@argotpartners.com
Firm Analyst Email
Roth Capital Partners
Scott R Henry, CFA shenry@roth.com
JMP Securities
Jason Butler, Ph.D. jbutler@jmpsecurities.com
Dawson James Securities, Inc.
Robert Wasserman rwasserman@dawsonjames.com
Lazard Capital Markets
William Tanner, Ph.D. william.tanner@lazardcap.com
Ascendiant Capital Markets
George Santana, CFA gsantana@ascendiant.com
Eicoman and DG Thank you for all your knowledge
I'm wondering if the management of APRI is as smart as you guys relative to what needs to be discussed Wednesday. Perhaps either of you guys or both would like to email Pascoe and IR these bullet points that need to be disclosed. Maybe they are not planning on being as transparent as we would like. A small shove from you in that direction might be beneficial.
Just some random thoughts while watching football.
Again, thanks for all of your great discussions.
Beau... Thank you for the preliminary Info....
I anxiously await the real GOLD report!
Thank you in advance.
I hope they gave you a gold nugget as a memento.. (Not too big,though)
GoCougs.....
I'd like to hope it is following the theory that "Volume preceeds Price." (hopefully to the upside!!!)
Maybe Frost bought some on the open market.
What about Red Chip to market us?
They seem to have a big following, write research reports and conduct investor conferences..
Crookedneck...
How much would it cost to have a banner ad on the top of pages on IHUB message boards? And do you think NRTI would be interested in showcasing MSE in that manner?
I have seen a lot of products and even some other stocks such as North Bay Resources, a gold mining company.
Wouldn't it look nice to see Inergetics name as we are reading the message boards? Just a thought.
Inergetics Continues Martha Stewart Essentials Distribution Build
NEWARK, N.J., Oct. 30, 2013 /PRNewswire/ -- Inergetics (NRTI), a leading developer of nutritional supplements, announces that Cardinal Health and Hy-Vee agreed to add the new Martha Stewart Essentials line of supplements to their respective nutritional portfolios this fall.
"Cardinal Health, distributor to thousands of retail doors is on board with this new venture," says Michael James, CEO. "Cardinal Health is a premier organization and we're proud to partner with them as we move forward in building Martha Stewart Essentials distribution."
Hy-Vee is the first food chain bringing in the line and it will be the first time the Martha Stewart brand will adorn the shelves of food stores. Hy-Vee will feature Martha Stewart Essentials displays in their nutritional section to ensure brand visibility.
"Martha Stewart Essentials is generating real excitement in this burgeoning category and we're proud of the fact that we have this American icon as part of our portfolio," says Marshall Post, EVP.
"Martha Stewart, author of her latest national best-selling book, Living the Good Long Life, understands healthy living. She lives and breathes it and knows today's consumers have been waiting for her to enter this market for some time," says CMO, Jim Kras.
Martha Stewart Essentials is a line of supplements developed to address women concerned with supporting their overall health, staying active into old age while helping keep their health care costs down. The line features six condition-specific, whole-food-based formulas, which include: Multivitamin, Graceful Aging, Hair, Skin & Nails, Digestive Health, Bone Support, and Menopause Support.
Inergetics plans to aggressively support the line with National FSIs (free-standing insert), print and digitally integrated efforts designed to accelerate consumer trial.
About Inergetics, Inc.
Inergetics, Inc. is a leading developer of nutritional supplements for the clinical health, sports supplement and mass markets. Inergetics product portfolio features Surgex® Sports Nutrition, the preferred sports nutrition of Army Sports, Bikini Ready®, a leader in weight loss lifestyle solutions and SlimTrim™, the affordable, premium value diet brand. To learn more about Inergetics, visit www.inergetics.com, and the Inergetics brands' websites at: www.surgexsports.com, www.surgexsportsblitz.com, www.slimtrim1.com, www.slimtrim.net, www.bikinireadylifestyle.com, www.kahunasands.com
About Cardinal Health, Inc.
Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a $101 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. Ranked #19 on the Fortune 500, Cardinal Health employs 34,000 people worldwide. More information about the company may be found at www.cardinalhealth.com and @CardinalHealth on Twitter.
About Hy-Vee, Inc.
Hy-Vee, Inc. is an employee-owned chain of 230+ supermarkets located in eight states throughout the United States including: Iowa, Kansas, Minnesota, Missouri, Nebraska, South Dakota and Wisconsin. Hy-Vee employs over 60,000 individuals and is the largest employer in the state of Iowa. The company has annual sales of over $7.3 billion. In 2011 Hy-Vee ranked 48th on Forbes magazine's annual list of the largest privately owned companies in the United States.
About Martha Stewart Living Omnimedia, Inc.
Martha Stewart Living Omnimedia, Inc, is a diversified media and merchandising company, inspiring and engaging consumers with unique lifestyle content and distinctive products. The Company reaches approximately 100 million consumers across all media platforms each month and has a growing retail presence in thousands of retail locations. MSLO's media brands, available across multiple platforms, include Martha Stewart Living, Martha Stewart Weddings, and Everyday Food; the Company also offers books and utility Apps. MSLO's television and video programming includes "Martha Stewart's Cooking School" and "Martha Bakes" series on PBS, in addition to new made-for-the-web video and a vast library of how-to content available online. Martha Live, a new radio show hosted by Martha Stewart, airs every weekday on SIRIUS XM Channel 107. MSLO also designs high-quality Martha Stewart products in a range of lifestyle categories available through select retailers, including The Home Depot, Macy's, JCPenney, Staples (together with Avery), PetSmart, Michaels and Jo-Ann Fabric & Craft Stores. The MSLO family of brands also includes Chef Emeril Lagasse's media and merchandising properties.
Additional information about MSLO is at www.marthastewart.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of Inergetics set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects," "forecasts," or similar expressions, are "forward-looking statements." Although Inergetics' management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause Inergetics' future results to differ materially from those anticipated. Inergetics assumes no obligation to update any of the information contained or referenced in this press release.
SOURCE Inergetics, Inc.
Copyright 2013 PR Newswire
There's a new health related show on FOXNEWS
called A Healthy You on Saturdays and repeated on Sundays. I think this might be a great venue for Ms Stewart to talk about MSE.
Carol Alt is a 52 year old Internationally know model who began this show about a month ago. Below see what her website says about the show.
ABOUT THE SHOW
Supermodel and lifestyle expert Carol Alt will interview guest professionals, celebrities and everyday people and share her signature tips for maintaining health and wellness.
Likety Split... I'm with you..
I'd like to see Ms Stewart get out there and give some exposure to these supplements. She might want to consider appearing on Dr. Oz or the Doctors (or both) and give out free samples while talking about benefits.
Maybe she might even do a few segments on Home Shopping or QVC giving a multiple bottle discount.
Exposure is the name of the game.
CN... GREAT Summary.. THANK YOU VERY MUCH
Maxim initiates a "BUY"
IsoRay trades up on Maxim initiation that sees 188% upside • 1:21 PM
Shares of IsoRay (ISR +3.1%) trade up after Maxim Group initiates the isotope-based cancer treatment producer at Buy with a PT of $1.50. Maxim is the first firm to cover IsoRay.
From yesterday's close, that implies a potential upside of 188%.
CN...Reading the intro page
and I have to say you do a GREAT JOB! Thanks
I noticed that a member of our board, James Delucia is head of his own marketing/advertising agency,etc ARJames Media..Based in NJ. So I would guess we have some pretty good minds with a vested interest, providing some guidance in that area, NO? They have a pretty nice client list.
Also reading the News Release about Martha attending the Aug NACDS expo in Las Vegas. Wondering how many of those chains, stores, outlets are serviced by Cardinal Health.
By the way, when you get some time, maybe you could add that PR about the Cardinal Relationship.
Too much spare time today!
CN.. Celebrity idea...
A former wholesome athlete (Now that's an oxymoron, if I ever heard)
or coach.. Don Shula like, but someone younger.
Maybe Bret Favre or Dan Marino.. Someone with a national identity.
CN.. You saved $75 on your NRTI purchase...
"Bought 15,000 @ $.14 despite a bid of $.145. MAXM holding strong at $.142 and not moving down despite Nite dropping down to $.14 ask. Cheers! "
You should go to the nearest Walgreens and buy 4 bottles of MSO supplements!
All kidding aside, I know these supplements are geared towards women, but do you think there will be anything for men in the forseable future. I know I would switch over in a heartbeat. I always like to buy something made or sold by the companies I own.
Dennis.. I hear what you are saying...
"Thre are things Mr. James probably can't get into because of privacy matters with customers."
I'm sure that the names will be released in due time, it only makes sense if you want to sell product, people have to know where to go to buy it. Not everyone reads this message board like we do. The masses will need to be informed in advertising. If these 'customers' want to keep it private that they are selling MSO supplements, they're not going to sell too much!
Again, I know the names will be revealed soon, but I would have liked to have seen it sooner.
CN.. Thanks for all your info....
When you speak with Mr. James are you going to ask him what stores or outlets Cardinal Health will be delivering MSO product to? Also see if this deal with Cardinal includes the distribution of our other products such as Surgex and Slim Trim and Bikini Ready. Maybe GNC is in the mix or similar Health stores. Look forward to your responses from him.
TIA